Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting an open-label Phase 1 study titled AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES. The study aims to assess the safety and effects of PF-08046037 alone or combined with sasanlimab in patients with advanced or metastatic cancers, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and pancreatic ductal adenocarcinoma. This research is significant as it explores potential new treatments for these challenging conditions.
The interventions being tested are PF-08046037, administered intravenously, and sasanlimab, given subcutaneously. These drugs are intended to treat advanced malignancies by potentially improving patient outcomes.
The study follows a non-randomized, sequential intervention model with no masking, focusing on treatment. It involves dose escalation, optimization, and expansion phases to determine the optimal dosing strategy for both monotherapy and combination therapy.
The study began on May 6, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical trial update could influence Pfizer’s stock performance and investor sentiment, as successful outcomes may enhance Pfizer’s oncology portfolio. Investors should also consider the competitive landscape, as advancements in cancer treatment are highly sought after in the pharmaceutical industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.